[10-K/A] Upland Software, Inc. Amends Annual Report
Filing Impact
Filing Sentiment
Form Type
10-K/A
Rhea-AI Filing Summary
Form 8-K overview
Select Medical Holdings Corp. (NYSE: SEM) filed an 8-K dated 31-Jul-2025.
- Item 2.02 鈥� Results of Operations: the company furnished a 31-Jul-25 press release with Q2-25 financial results and schedules (Ex. 99.1). The actual numbers are not included in the filing text and therefore cannot be assessed here.
- Item 8.01 鈥� Other Events: the Board declared a regular cash dividend of $0.0625 per share, payable 28-Aug-25 to holders of record on 13-Aug-25.
No additional business updates, guidance, or transaction details were provided. The information is furnished, not filed, thus limiting Exchange Act liability.
Panoramica del Modulo 8-K
Select Medical Holdings Corp. (NYSE: SEM) ha presentato un modulo 8-K datato 31-lug-2025.
- Voce 2.02 鈥� Risultati Operativi: la societ脿 ha fornito un comunicato stampa del 31-lug-25 con i risultati finanziari del Q2-25 e relativi prospetti (Ex. 99.1). I dati effettivi non sono inclusi nel testo della presentazione e pertanto non possono essere valutati qui.
- Voce 8.01 鈥� Altri Eventi: il Consiglio ha dichiarato un dividendo in contanti ordinario di $0,0625 per azione, pagabile il 28-ago-25 agli azionisti registrati al 13-ago-25.
Non sono stati forniti ulteriori aggiornamenti aziendali, previsioni o dettagli sulle transazioni. L'informazione 猫 fornita, non depositata, limitando cos矛 la responsabilit脿 ai sensi dell'Exchange Act.
Resumen del Formulario 8-K
Select Medical Holdings Corp. (NYSE: SEM) present贸 un 8-K fechado el 31-jul-2025.
- 脥tem 2.02 鈥� Resultados de Operaciones: la compa帽铆a proporcion贸 un comunicado de prensa del 31-jul-25 con los resultados financieros del segundo trimestre de 2025 y anexos (Ex. 99.1). Los n煤meros reales no est谩n incluidos en el texto de la presentaci贸n y por lo tanto no pueden ser evaluados aqu铆.
- 脥tem 8.01 鈥� Otros Eventos: la Junta declar贸 un dividendo en efectivo regular de $0.0625 por acci贸n, pagadero el 28-ago-25 a los accionistas registrados al 13-ago-25.
No se proporcionaron actualizaciones comerciales adicionales, pron贸sticos ni detalles de transacciones. La informaci贸n se suministra, no se presenta formalmente, limitando as铆 la responsabilidad bajo la Exchange Act.
Form 8-K 臧滌殧
Select Medical Holdings Corp. (NYSE: SEM)電� 2025雲� 7鞗� 31鞚检瀽 8-K毳� 鞝滌稖頄堨姷雼堧嫟.
- 頃 2.02 鈥� 鞓侅梾 鞁れ爜: 須岇偓電� 2025雲� 7鞗� 31鞚检瀽 氤措弰鞛愲鞕� 2025雲� 2攵勱赴 鞛 瓴瓣臣 氚� 鞚检爼(Ex. 99.1)鞚� 鞝滉车頄堨姷雼堧嫟. 鞁れ牅 靾橃箻電� 鞝滌稖 氍胳劀 氤鸽鞐� 韽暔霅橃柎 鞛堨 鞎婌晞 鞐赴靹� 韽夑皜頃� 靾� 鞐嗢姷雼堧嫟.
- 頃 8.01 鈥� 旮绊儉 靷贝: 鞚挫偓须岆姅 欤茧嫻 $0.0625鞚� 鞝曣赴 順勱笀 氚半嫻旮堨潉 靹犾柛頄堨溂氅�, 2025雲� 8鞗� 28鞚检棎 2025雲� 8鞗� 13鞚� 旮办 欤检＜鞐愱矊 歆�旮夒悹 鞓堨爼鞛呺媹雼�.
於旉皜鞝侅澑 靷梾 鞐呺嵃鞚错姼, 臧�鞚措摐霛检澑 霕愲姅 瓯半灅 靹鸽秬靷暛鞚� 鞝滉车霅橃 鞎婌晿鞀惦媹雼�. 鞚� 鞝曤炒電� 鞝滌稖霅� 瓴冹澊 鞎勲媹霛� 鞝滉车霅� 瓴冹溂搿�, Exchange Act鞐� 霐半ジ 毂呾瀯鞚� 鞝滍暅霅╇媹雼�.
Vue d'ensemble du formulaire 8-K
Select Medical Holdings Corp. (NYSE : SEM) a d茅pos茅 un 8-K dat茅 du 31 juil. 2025.
- Article 2.02 鈥� R茅sultats d'exploitation : la soci茅t茅 a fourni un communiqu茅 de presse dat茅 du 31 juil. 25 avec les r茅sultats financiers du T2-25 et les annexes (Ex. 99.1). Les chiffres r茅els ne sont pas inclus dans le texte du d茅p么t et ne peuvent donc pas 锚tre 茅valu茅s ici.
- Article 8.01 鈥� Autres 茅v茅nements : le conseil d'administration a d茅clar茅 un dividende en esp猫ces r茅gulier de 0,0625 $ par action, payable le 28 ao没t 25 aux d茅tenteurs inscrits au 13 ao没t 25.
Aucune mise 脿 jour commerciale suppl茅mentaire, pr茅visions ou d茅tails de transaction n'ont 茅t茅 fournis. L'information est fournie, non d茅pos茅e, limitant ainsi la responsabilit茅 en vertu de l'Exchange Act.
脺berblick 眉ber Formular 8-K
Select Medical Holdings Corp. (NYSE: SEM) reichte ein 8-K mit Datum 31. Juli 2025 ein.
- Punkt 2.02 鈥� Betriebsergebnisse: Das Unternehmen stellte eine Pressemitteilung vom 31.07.25 mit den Finanzergebnissen f眉r das zweite Quartal 2025 und Anlagen (Ex. 99.1) zur Verf眉gung. Die tats盲chlichen Zahlen sind im Text der Einreichung nicht enthalten und k枚nnen daher hier nicht bewertet werden.
- Punkt 8.01 鈥� Sonstige Ereignisse: Der Vorstand erkl盲rte eine regul盲re Bardividende von $0,0625 pro Aktie, zahlbar am 28.08.25 an die am 13.08.25 eingetragenen Aktion盲re.
Es wurden keine weiteren Gesch盲ftsaktualisierungen, Prognosen oder Transaktionsdetails bereitgestellt. Die Informationen werden bereitgestellt, nicht eingereicht, wodurch die Haftung nach dem Exchange Act eingeschr盲nkt wird.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine 8-K; dividend maintained, no financial figures disclosed鈥攏eutral impact.
The filing simply alerts investors to a separate press release containing Q2-25 results and notes continuation of the company鈥檚 long-standing $0.0625 quarterly dividend. Without the underlying earnings data, it is impossible to judge operational performance or dividend coverage. The maintained payout suggests stability but conveys little incremental information. Impact on valuation and sentiment should be minimal until the actual financials are reviewed.
Panoramica del Modulo 8-K
Select Medical Holdings Corp. (NYSE: SEM) ha presentato un modulo 8-K datato 31-lug-2025.
- Voce 2.02 鈥� Risultati Operativi: la societ脿 ha fornito un comunicato stampa del 31-lug-25 con i risultati finanziari del Q2-25 e relativi prospetti (Ex. 99.1). I dati effettivi non sono inclusi nel testo della presentazione e pertanto non possono essere valutati qui.
- Voce 8.01 鈥� Altri Eventi: il Consiglio ha dichiarato un dividendo in contanti ordinario di $0,0625 per azione, pagabile il 28-ago-25 agli azionisti registrati al 13-ago-25.
Non sono stati forniti ulteriori aggiornamenti aziendali, previsioni o dettagli sulle transazioni. L'informazione 猫 fornita, non depositata, limitando cos矛 la responsabilit脿 ai sensi dell'Exchange Act.
Resumen del Formulario 8-K
Select Medical Holdings Corp. (NYSE: SEM) present贸 un 8-K fechado el 31-jul-2025.
- 脥tem 2.02 鈥� Resultados de Operaciones: la compa帽铆a proporcion贸 un comunicado de prensa del 31-jul-25 con los resultados financieros del segundo trimestre de 2025 y anexos (Ex. 99.1). Los n煤meros reales no est谩n incluidos en el texto de la presentaci贸n y por lo tanto no pueden ser evaluados aqu铆.
- 脥tem 8.01 鈥� Otros Eventos: la Junta declar贸 un dividendo en efectivo regular de $0.0625 por acci贸n, pagadero el 28-ago-25 a los accionistas registrados al 13-ago-25.
No se proporcionaron actualizaciones comerciales adicionales, pron贸sticos ni detalles de transacciones. La informaci贸n se suministra, no se presenta formalmente, limitando as铆 la responsabilidad bajo la Exchange Act.
Form 8-K 臧滌殧
Select Medical Holdings Corp. (NYSE: SEM)電� 2025雲� 7鞗� 31鞚检瀽 8-K毳� 鞝滌稖頄堨姷雼堧嫟.
- 頃 2.02 鈥� 鞓侅梾 鞁れ爜: 須岇偓電� 2025雲� 7鞗� 31鞚检瀽 氤措弰鞛愲鞕� 2025雲� 2攵勱赴 鞛 瓴瓣臣 氚� 鞚检爼(Ex. 99.1)鞚� 鞝滉车頄堨姷雼堧嫟. 鞁れ牅 靾橃箻電� 鞝滌稖 氍胳劀 氤鸽鞐� 韽暔霅橃柎 鞛堨 鞎婌晞 鞐赴靹� 韽夑皜頃� 靾� 鞐嗢姷雼堧嫟.
- 頃 8.01 鈥� 旮绊儉 靷贝: 鞚挫偓须岆姅 欤茧嫻 $0.0625鞚� 鞝曣赴 順勱笀 氚半嫻旮堨潉 靹犾柛頄堨溂氅�, 2025雲� 8鞗� 28鞚检棎 2025雲� 8鞗� 13鞚� 旮办 欤检＜鞐愱矊 歆�旮夒悹 鞓堨爼鞛呺媹雼�.
於旉皜鞝侅澑 靷梾 鞐呺嵃鞚错姼, 臧�鞚措摐霛检澑 霕愲姅 瓯半灅 靹鸽秬靷暛鞚� 鞝滉车霅橃 鞎婌晿鞀惦媹雼�. 鞚� 鞝曤炒電� 鞝滌稖霅� 瓴冹澊 鞎勲媹霛� 鞝滉车霅� 瓴冹溂搿�, Exchange Act鞐� 霐半ジ 毂呾瀯鞚� 鞝滍暅霅╇媹雼�.
Vue d'ensemble du formulaire 8-K
Select Medical Holdings Corp. (NYSE : SEM) a d茅pos茅 un 8-K dat茅 du 31 juil. 2025.
- Article 2.02 鈥� R茅sultats d'exploitation : la soci茅t茅 a fourni un communiqu茅 de presse dat茅 du 31 juil. 25 avec les r茅sultats financiers du T2-25 et les annexes (Ex. 99.1). Les chiffres r茅els ne sont pas inclus dans le texte du d茅p么t et ne peuvent donc pas 锚tre 茅valu茅s ici.
- Article 8.01 鈥� Autres 茅v茅nements : le conseil d'administration a d茅clar茅 un dividende en esp猫ces r茅gulier de 0,0625 $ par action, payable le 28 ao没t 25 aux d茅tenteurs inscrits au 13 ao没t 25.
Aucune mise 脿 jour commerciale suppl茅mentaire, pr茅visions ou d茅tails de transaction n'ont 茅t茅 fournis. L'information est fournie, non d茅pos茅e, limitant ainsi la responsabilit茅 en vertu de l'Exchange Act.
脺berblick 眉ber Formular 8-K
Select Medical Holdings Corp. (NYSE: SEM) reichte ein 8-K mit Datum 31. Juli 2025 ein.
- Punkt 2.02 鈥� Betriebsergebnisse: Das Unternehmen stellte eine Pressemitteilung vom 31.07.25 mit den Finanzergebnissen f眉r das zweite Quartal 2025 und Anlagen (Ex. 99.1) zur Verf眉gung. Die tats盲chlichen Zahlen sind im Text der Einreichung nicht enthalten und k枚nnen daher hier nicht bewertet werden.
- Punkt 8.01 鈥� Sonstige Ereignisse: Der Vorstand erkl盲rte eine regul盲re Bardividende von $0,0625 pro Aktie, zahlbar am 28.08.25 an die am 13.08.25 eingetragenen Aktion盲re.
Es wurden keine weiteren Gesch盲ftsaktualisierungen, Prognosen oder Transaktionsdetails bereitgestellt. Die Informationen werden bereitgestellt, nicht eingereicht, wodurch die Haftung nach dem Exchange Act eingeschr盲nkt wird.
F
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
(Amendment No. 1)
For the fiscal year ended December 31 , 2024
OR
Commission File Number 001-36720
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) | ||||
(512 ) 960-1010
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ¨ | x | |||||||||
| Non-accelerated filer | ¨ | Smaller reporting company | |||||||||
| Emerging growth company | |||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No x
The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $60.2 million based upon the closing price of $2.49 of such common stock on the Nasdaq Global Market on June 28, 2024 (the last business day of the registrant’s most recently completed second fiscal quarter). Shares of common stock held as of June 30, 2024 by each director and executive officer of the registrant, as well as shares held by each holder of 10% of the common stock known to the registrant, have been excluded for purposes of the foregoing calculation. This determination of affiliate status is not a conclusive determination for other purposes.
As of July 29, 2025, 28,772,095 shares of the registrant’s Common Stock were outstanding.
Documents incorporated by reference:
1
Explanatory Note
Upland Software, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) to amend the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 12, 2025 (the “Original 2024 Form 10-K”). The purpose of this Amendment No. 1 is to correct Part II, Item 9A. Controls and Procedures of the Company’s Original 2024 Form 10-K, which inadvertently omitted a statement disclosing the conclusions of the Company’s principal executive officer and principal financial officer regarding the effectiveness of the Company’s disclosure controls and procedures as of December 31, 2024. This Amendment No. 1 corrects such omission and amends and replaces Part II, Item 9A. Controls and Procedures of the Original 2024 Form 10-K in its entirety.
In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), this Amendment No. 1 also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto.
Except as described above, this Amendment No. 1 does not amend, modify, or otherwise update any other information in the Original 2024 Form 10-K and does not reflect events occurring after the filing of the Original 2024 Form 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original 2024 Form 10-K and the Company’s other filings with the SEC.
1
PART II
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Pursuant to Rule 13a-15(b) of the Exchange Act, our management, including our Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial officer, respectively), has evaluated our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of December 31, 2024.
Our management does not expect that our disclosure controls and procedures will prevent or detect all errors and all fraud. Disclosure controls and procedures, no matter how well designed, operated and managed, can provide only reasonable assurance that the objectives of the disclosure controls and procedures are met. Because of the inherent limitations of disclosure controls and procedures, no evaluation of such disclosure controls and procedures can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.
Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2024.
Management Report on Internal Control Over Financial Reporting
Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) of the Exchange Act. The Company’s internal control system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Due to its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.
Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024, using the criteria set forth in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) . Based on that assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2024 based on those criteria.
Changes in Internal Control over Financial Reporting
There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the year ended December 31, 2024 other than items described below related to our remediation actions, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Remediation of Prior Material Weakness in Internal Control Over Financial Reporting
As of December 31, 2023, our management identified and disclosed a material weakness in the design and operation of a management review control over prospective financial information used in the Company’s goodwill impairment assessment, and specifically, not sufficiently performing and documenting the reasonableness of significant assumptions used therein.
During 2024, our management was actively engaged in remediation efforts to address the material weakness noted above. The Company implemented the following improvements:
•The design, including the precision, of the management review control over the significant assumptions used to prepare the prospective financial information used in the Company’s goodwill impairment assessment was updated to ensure the sufficiency of the control procedures. Specifically, the procedures over the significant assumptions are appropriately detailed to allow management to assess the operating effectiveness of the control.
•Sufficient documentation was prepared, reviewed and retained over the Company’s annual goodwill impairment assessment performed as of October 1, 2024.
Based on the actions taken and the testing and evaluation of the effectiveness of our internal control over financial reporting, our management has concluded the material weakness identified in the prior year no longer existed as of December 31, 2024.
The independent registered public accounting firm of Ernst & Young LLP, as auditors of the Company’s consolidated financial statements, has issued an attestation report on the effectiveness of the Company’s internal control over financial reporting, included herein.
2
PART IV
Item 15. Exhibits and Financial Statement Schedules
See Exhibit Index at the end of this Annual Report on Form 10-K/A, which is incorporated by reference.
EXHIBIT INDEX
| Exhibit No. | Description of Exhibit | ||||
31.3* | Certification of the Principal Executive Officer Required Under Rules 13a-14(a) and 15d-14(a) of the Securities Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
31.4* | Certification of the Principal Financial Officer Required Under Rules 13a-14(a) and 15d-14(a) of the Securities Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ||||
* Filed herewith.
3
SIGNATURES
Pursuant to the requirement of Sections 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: July 31, 2025
| Upland Software, Inc. | ||||||||
| By: | /s/ Michael D. Hill | |||||||
| Michael D. Hill | ||||||||
| Chief Financial Officer | ||||||||
4
Source:
Upland Software
NASDAQ:UPLD
UPLD Rankings
UPLD Latest News
UPLD Latest SEC Filings
Jul 31, 2025
[8-K] Upland Software, Inc. Reports Material Event
Jul 28, 2025
[8-K] Upland Software, Inc. Reports Material Event
Jul 14, 2025
[8-K] Upland Software, Inc. Reports Material Event
UPLD Stock Data
64.09M
20.48M
27.23%
53.96%
0.76%
Software - Application
Services-prepackaged Software
United States
AUSTIN